Published in Law and Health Weekly, October 8th, 2005
The letter, which is being submitted as an 8-K with the Securities and Exchange Commission, highlights several key developments currently underway.
Hemispherx is implementing a three-phase strategy in its manufacturing process of Ampligen. The first component in this process highlighted in the stockholder letter is the establishment of production of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.